Search

Your search keyword '"Drenth, Joost"' showing total 18 results
Start Over Author "Drenth, Joost" Language undetermined
18 results on '"Drenth, Joost"'

1. Additional file 1 of Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders, Romée J. A. L. M., Stoelinga, Anna E. C., Gevers, Tom J. G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J. M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A. M. C. Baven, Beuers, Ulrich H. W., van der Meer, Adriaan J., van Gerven, Nicole M. F., Sijtsma, Marijn G. M., Verwer, Bart J., Gisbertz, Ingrid A. M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M. J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P. H.

Abstract

Additional file 1. Spirit checklist.

Published
2023
Full Text
View/download PDF

2. Additional file 3 of Novel GANAB variants associated with polycystic liver disease

Author

Liyanne F. M. Van De Laarschot, Morsche, René H. M. Te, Hoischen, Alexander, Venselaar, Hanka, Roelofs, Hennie M., Wybrich R. Cnossen, Banales, Jesus M., Roepman, Ronald, and Drenth, Joost P. H.

Abstract

Additional file 3. DNA and protein expression analysis of GIIα. DNA expression of GIIα Wild Type intron (WT) and mutant intron (MT intron) was analysed using qPCR with B-actin (ACTB) as reference. WT expression was 1.46 times higher than MT intron. On Western Blot expression of WT protein was 4 times higher than MT intron protein. In absolute numbers protein expression of WT intron was 2.67 times higher than MT intron protein

Published
2020
Full Text
View/download PDF

4. Supplementary_files – Supplemental material for Systematic review with meta-analysis: age-related malignancy detection rates at upper gastrointestinal endoscopy

Author

Jong, Judith J. De, Lantinga, Marten A., Thijs, Ina M. E., Reuver, Philip R. De, and Drenth, Joost P. H.

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_files for Systematic review with meta-analysis: age-related malignancy detection rates at upper gastrointestinal endoscopy by Judith J. de Jong, Marten A. Lantinga, Ina M. E. Thijs, Philip R. de Reuver and Joost P. H. Drenth in Therapeutic Advances in Gastroenterology

Published
2020
Full Text
View/download PDF

7. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations

Author

Weersink, Rianne A., Burger, David M., Hayward, Kelly L., Taxis, Katja, Drenth, Joost P.H., and Borgsteede, Sander D.

Abstract

Introduction: The global burden of cirrhosis is rising, and clinicians increasingly face the challenge of safely prescribing medicines for complications of hepatic disease and comorbidities. Prescribing in patients with cirrhosis is complicated by alterations that can occur in the pharmacology of medicines. Areas covered: This paper provides an overview of current knowledge on the pharmacokinetics and pharmacodynamics of medicines in patients with cirrhosis. We describe the pathophysiological changes that occur and their consequences on pharmacokinetic parameters. We explain that the influence of cirrhosis on the pharmacokinetics depends on several drug and patient characteristics. Patients with cirrhosis also have an increased susceptibility to some toxicological effects of medicines, such as renal impairment and hematological toxicity, which we describe in detail. In addition, we discuss approaches to apply this knowledge in practice and improve safe medication use in patients with cirrhosis. Expert opinion: Tailored pharmacotherapy is needed to ensure safe and appropriate use of medicines in patients with cirrhosis. Clinicians are supported by freely available recommendations on safe drug use in cirrhosis published on a website. In addition, a regular evaluation of medication use in patients with cirrhosis could resolve and prevent medication-related problems.

Published
2019
Full Text
View/download PDF

8. Common variants in glyoxalase I do not increase chronic pancreatitis risk

Author

Kaune, Tom, Hollenbach, Marcus, Keil, Bettina, Chen, Jian-Min, Masson, Emmanuelle, Becker, Carla, Damm, Marko, Ruffert, Claudia, Grützmann, Robert, Hoffmeister, Albrecht, te Morsche, Rene H. M., Cavestro, Giulia Martina, Zuppardo, Raffaella Alessia, Saftoiu, Adrian, Malecka-Panas, Ewa, Głuszek, Stanislaw, Bugert, Peter, Lerch, Markus M., Weiss, Frank Ulrich, Zou, Wen-Bin, Liao, Zhuan, Hegyi, Peter, Drenth, Joost PH, Riedel, Jan, Férec, Claude, Scholz, Markus, Kirsten, Holger, Tóth, Andrea, Ewers, Maren, Witt, Heiko, Griesmann, Heidi, Michl, Patrick, and Rosendahl, Jonas

Subjects
ddc
Published
2018

9. Supplementary_Material – Supplemental material for Drug holiday in patients with polycystic liver disease treated with somatostatin analogues

Author

Aerts, René M. M. Van, Kolkman, Marieke, Kievit, Wietske, Gevers, Tom J. G., Nevens, Frederik, and Drenth, Joost P. H.

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_Material for Drug holiday in patients with polycystic liver disease treated with somatostatin analogues by René M. M. van Aerts, Marieke Kolkman, Wietske Kievit, Tom J. G. Gevers, Frederik Nevens and Joost P. H. Drenth in Therapeutic Advances in Gastroenterology

Published
2018
Full Text
View/download PDF

10. Additional file 1: Table S1. of The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression

Author

Neijenhuis, Myrte, Kievit, Wietske, Perrone, Ronald, Sloan, Jeff, Erwin, Patricia, Murad, Mohammad, Gevers, Tom, Hogan, Marie, and Drenth, Joost

Subjects
humanities
Abstract

Example of the search strategy (MEDLINE). Table S2. Risk of bias assessment QoL studies. (DOCX 18 kb)

Published
2017
Full Text
View/download PDF

11. Better survival of renal cell carcinoma in patients with inflammatory bowel disease

Author

Derikx, Lauranne A. A. P., Nissen, Loes H. C., Drenth, Joost P. H., van Herpen, Carla M., Kievit, Wietske, Verhoeven, Rob H. A., Mulders, Peter F. A., Hulsbergen-van de Kaa, Christina A., Boers-Sonderen, Marye J., van den Heuvel, Tim R. A., Pierik, Marieke, Nagtegaal, Iris D., Hoentjen, Frank, Kluin, P. M., Hogenes, M., Hamel, A. F., Natté, R., van Dijk, C. M., Kusters-Vandevelde, H. V. N., Sastrowijoto, S. H., Willig, A. P., Dijkstra, G., van der Meulen-de Jong, A. E., Vu, M. K., Cats, A., Haanen, J. B. A. G., van der Woude, C. J., Russel, M. G. V. M., Oldenburg, B., Meeuse, J. J., Corporaal, S., Zonneveld, A. M., Wahab, P. J., van den Hazel, S. J., Mares, W. G. N., Lieverse, R. J., Meijssen, M. A. C., Thuernau, K., Janik, D., van der Heide, H., Ponsioen, C. Y., Stokkers, P. C. F., Gastroenterology and Hepatology, Interne Geneeskunde, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
Male, Time Factors, Kaplan-Meier Estimate, urologic and male genital diseases, Inflammatory bowel disease, Crohn Disease, Risk Factors, Renal cell carcinoma, Odds Ratio, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Medicine, Registries, Early Detection of Cancer, Netherlands, Aged, 80 and over, education.field_of_study, Age Factors, Middle Aged, Prognosis, Kidney Neoplasms, female genital diseases and pregnancy complications, Oncology, Cohort, Female, medicine.symptom, Immunosuppressive Agents, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, renal cell carcinoma, Pancolitis, medicine.medical_specialty, Population, immunosuppressive therapy, Risk Assessment, Immunocompromised Host, Predictive Value of Tests, inflammatory bowel disease, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, education, Carcinoma, Renal Cell, Aged, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, Tumor Necrosis Factor-alpha, business.industry, Retrospective cohort study, Odds ratio, medicine.disease, digestive system diseases, Surgery, Cancer registry, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Multivariate Analysis, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Colitis, Ulcerative, Clinical Research Paper, business
Abstract

// Lauranne A.A.P. Derikx 1 , Loes H.C. Nissen 1 , Joost P.H. Drenth 1 , Carla M. van Herpen 2 , Wietske Kievit 3 , Rob H.A. Verhoeven 4 , Peter F.A. Mulders 5 , Christina A. Hulsbergen-van de Kaa 6 , Marye J. Boers-Sonderen 2 , Tim R.A. van den Heuvel 7 , Marieke Pierik 7 , Iris D. Nagtegaal 6 , Frank Hoentjen 1 , On behalf of the Dutch Initiative on Crohn and Colitis (ICC), PALGA group and IBD/RCC group 1 Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud university medical centre, Nijmegen, The Netherlands 2 Department of Medical Oncology, Radboud university medical centre, Nijmegen, The Netherlands 3 Radboud Institute for Health Sciences, Radboud university medical centre, Nijmegen, The Netherlands 4 Netherlands comprehensive cancer organization / Netherlands Cancer Registry, Utrecht, The Netherlands 5 Department of Urology, Radboud university medical centre, Nijmegen, The Netherlands 6 Department of Pathology, Radboud university medical centre, Nijmegen, The Netherlands 7 Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands Correspondence to: Lauranne A.A.P. Derikx, e-mail: Lauranne.Derikx@radboudumc.nl Keywords: inflammatory bowel disease, renal cell carcinoma, immunosuppressive therapy Received: June 30, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Background: Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). Cancer specific data regarding risk and outcome are scarce and data for renal cell carcinoma (RCC) are lacking. We aimed(1) to identify risk factors for RCC development in IBD patients (2) to compare RCC characteristics, outcome and survival between IBD patients and the general population. Methods: A PALGA (Dutch Pathology Registry) search was performed to establish a case group consisting of all IBD patients with incident RCC in The Netherlands (1991–2013). Cases were compared with two separate control groups: (A) with a population-based IBD cohort for identification of risk factors (B) with a RCC cohort from the general population to compare RCC characteristics and outcomes. Results: 180 IBD patients with RCC were identified. Pancolitis (OR 1.8–2.5), penetrating Crohn’s disease (OR 2.8), IBD related surgery (OR 3.7–4.5), male gender (OR 3.2–5.0) and older age at IBD onset (OR 1.0–1.1) were identified as independent risk factors for RCC development. IBD patients had a significantly lower age at RCC diagnosis ( p < 0.001), lower N-stage ( p = 0.025), lower M-stage ( p = 0.020) and underwent more frequently surgical treatment for RCC ( p < 0.001) compared to the general population. This translated into a better survival ( p = 0.026; HR 0.7) independent of immunosuppression. Conclusions: IBD patients with a complex phenotype are at increased risk to develop RCC. They are diagnosed with RCC at a younger age and at an earlier disease stage compared to the general population. This translates into a better survival independent of immunosuppressive or anti-TNFα therapy.

Published
2015

12. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis

Author

Heiko, Witt, Miklos Sahin Toth, Olfert, Landt, Jian Min Chen, Thilo, Kahne, Drenth, Joost P. H., Zoltan, Kukor, Edit, Szepessy, Walter, Halangk, Stefan, Dahm, Klaus, Rohde, Hans Ulrich Schulz, Cedric Le Marechal, Nejat, Akar, Ammann, Rudolf W., Kaspar, Truninger, Mario, Bargetzi, Eesh, Bhatia, Carlo, Castellani, Giulia Martina Cavestro, Milos, Cerny, DESTRO-BISOL, Giovanni, Spedini, Gabriella, Hans, Eiberg, Jansen, Jan B. M. J., Monika, Koudova, Eva, Rausova, Milan, Macek, Macek Jr, M., Nuria, Malats, Real, Francisco X., Hans Jurgen Menzel, Pedro, Moral, Roberta, Galavotti, Pier Franco Pignatti, Olga, Rickards, Julius, Spicak, Narcis Octavian Zarnescu, Wolfgang, Bock, Gress, Thomas M., Helmut, Friess, Johann, Ockenga, Hartmut, Schmidt, Roland, Pfutzer, Matthias, Lohr, Peter, Simon, Frank Ulrich Weiss, Lerch, Markus M., Niels, Teich, Volker, Keim, Thomas, Berg, Bertram, Wiedenmann, Werner, Luck, David Alexander Groneberg, Michael, Becker, Thomas, Keil, Andreas, Kage, Jana, Bernardova, Markus, Braun, Claudia, Guldner, Juliane, Halangk, Jonas, Rosendahl, Ulrike, Witt, Matthias, Treiber, Renate, Nickel, Claude, Ferec, Witt, H, SAHIN TOTH, M, Landt, O, Chen, Jm, Kahne, T, Drenth, Jp, Kukor, Z, Szepessy, E, Halangk, W, Dahm, S, Rohde, K, Schulz, Hu, LE MARECHAL, C, Akar, N, Ammann, Rw, Truninger, K, Bargetzi, M, Bhatia, E, Castellani, C, Cavestro, GIULIA MARTINA, Cerny, M, DESTRO BISOL, G, Spedini, G, Eiberg, H, Jansen, Jb, Koudova, M, Rausova, E, MACEK M., Jr, Malats, N, Real, Fx, Menzel, Hj, Moral, P, Galavotti, R, Pignatti, Pf, Rickards, O, Spicak, J, Zarnescu, No, Bock, W, Gress, Tm, Friess, H, Ockenga, J, Schmidt, H, Pfutzer, R, Lohr, M, Simon, P, Weiss, Fu, Lerch, Mm, Teich, N, Keim, V, Berg, T, Wiedenmann, B, Luck, W, Groneberg, Da, Becker, M, Keil, T, Kage, A, Bernardova, J, Braun, M, Guldner, C, Halangk, J, Rosendahl, J, Witt, U, Treiber, M, Nickel, R, and Ferec, C.

Subjects
trypsin inhibitor, Models, Molecular, Enteropeptidase, Pancreatic disease, Membrane transport and intracellular motility [NCMLS 5], arginine, genetic risk, chemistry.chemical_compound, Models, proteinosis, Trypsin, Pancreatic Secretory Trypsin Inhibitor, PRSS1 gene, enteropeptidase, medicine.diagnostic_test, adult, Hydrolysis, cationic trypsinogen, protection, unclassified drug, enzyme activity, female, priority journal, risk factor, CHRONIC PANCREATITIS, protein degradation, Trypsinogen, medicine.drug, medicine.medical_specialty, anionic trypsinogen, Proteolysis, Biology, Article, male, Internal medicine, Genetics, medicine, Matrix-Assisted Laser Desorption-Ionization, Humans, PRSS2, controlled study, human, Molecular gastro-enterology and hepatology [IGMD 2], gene, DNA Primers, Genetic polymorphism, catalysis, Base Sequence, Spectrometry, disease predisposition, Molecular, cationic trypsinogen prss1, glycine, pancreatic secretory trypsin inhibitor spink1, trypsin, trypsinogen, article, chronic pancreatitis, codon, genetic susceptibility, major clinical study, nucleotide sequence, Chronic Disease, Haplotypes, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Mass, medicine.disease, Tripsinogen, Tripsina, Settore BIO/18 - Genetica, Endocrinology, Genetic defects of metabolism [UMCN 5.1], Pancreatitis, chemistry, Genètica
Abstract

Chronic pancreatitis is a common inflammatory disease of the pancreas. Mutations in the genes encoding cationic trypsinogen (PRSS1) and the pancreatic secretory trypsin inhibitor (SPINK1) are associated with chronic pancreatitis. Because increased proteolytic activity owing to mutated PRSS1 enhances the risk for chronic pancreatitis, mutations in the gene encoding anionic trypsinogen (PRSS2) may also predispose to disease. Here we analyzed PRSS2 in individuals with chronic pancreatitis and controls and found, to our surprise, that a variant of codon 191 (G191R) is overrepresented in control subjects: G191R was present in 220/6,459 (3.4%) controls but in only 32/2,466 (1.3%) affected individuals (odds ratio 0.37; P = 1.1 x 10(-8)). Upon activation by enterokinase or trypsin, purified recombinant G191R protein showed a complete loss of trypsin activity owing to the introduction of a new tryptic cleavage site that renders the enzyme hypersensitive to autocatalytic proteolysis. In conclusion, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis. The initial experiments were supported by the DFG (Wi 2036/1-1). This work was supported by the Sonnenfeld-Stiftung, Berlin, Germany (to H.W.), the US National Institutes of Health (NIH) (grant DK058088 to M.S.-T.), INSERM (Institut National de la Santé et de la Recherche Médicale) and the Programme Hospitalier de Recherche Clinique (grant PHRC R 08-04 to C.F.)

Published
2006

13. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study

Author

van Keimpema, Loes, Nevens, Frederik, Adam, Rene, Porte, Robert J., Fikatas, Panagiotis, Becker, Thomas, Kirkegaard, Preben, Metselaar, Herold J., Drenth, Joost P. H., and Groningen Institute for Organ Transplantation (GIOT)

Subjects
polycystic liver disease, FENESTRATION, liver transplantation, treatment, KIDNEY-TRANSPLANTATION, VOLUME, MANAGEMENT, Membrane transport and intracellular motility [NCMLS 5], liver cyst, CYSTS, Molecular gastro-enterology and hepatology [IGMD 2]
Abstract

Item does not contain fulltext Patients with end-stage isolated polycystic liver disease (PCLD) suffer from incapacitating symptoms because of very large liver volumes. Liver transplantation (LT) is the only curative option. This study assesses the feasibility of LT in PCLD. We used the European Liver Transplant Registry (ELTR) database to extract demographics and outcomes of 58 PCLD patients. We used Kaplan-Meier survival analysis for survival rates. Severe abdominal pain (75%) was the most prominent symptom, while portal hypertension (35%) was the most common complication in PCLD. The explantation of the polycystic liver was extremely difficult in 38% of patients, because of presence of adhesions from prior therapy (17%). Karnofsky score following LT was 90%. The 1- and 5-year graft survival rate was 94.3% and 87.5%, while patient survival rate was 94.8% and 92.3%, respectively. Survival rates after LT for PCLD are good.

Published
2011

14. Additional file 1: of Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial

Author

Smeets, Xavier, Costa, David Da, Fockens, Paul, Mulder, Chris, Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco, Besselink, Marc, Vleggaar, Frank, Hulst, Rene Van Der, Poen, Alexander, Heine, Gerbrand, Venneman, Niels, Kolkman, Jeroen, Lubbertus Baak, RĂśmkens, Tessa, Dijk, Sven Van, Hallensleben, Nora, Vrie, Wim Van De, Seerden, Tom, Tan, Adriaan, Voorburg, Annet, Jan-Werner Poley, Witteman, Ben, Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem, Schwartz, Matthijs, Vrolijk, Jan, Verdonk, Robert, Foke Van Delft, Keulemans, Yolande, Goor, Harry Van, Drenth, Joost, and Geenen, Erwin Van

Subjects
3. Good health
Abstract

Definitions of secondary endpoints. Table S1. Severity of PEP according to Cotton and revised Atlanta criteria. Table S2. Local and systemic complications according to (revised) Atlanta criteria. Table S3. ERCP-related complications (adopted from Cotton). SPIRIT checklist. (DOCX 40 kb)

17. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author

George N. Dalekos, Cristina Rigamonti, Godolfino Miranda Zazueta, Ali Rıza Calışkan, Annarosa Floreani, Berat Ebik, Kadri Atay, Aylin Demirezer Bolat, Nazım Ekin, Eric M. Yoshida, Graciela Castro Narro, Fatih Güzelbulut, Murat Biyik, Manuel Mendizabal, Renumathy Dhanasekaran, Stefano Fagiuoli, Thomas D. Schiano, Ellina Lytvyak, Shalom Frager, Nataly Chris Escajadillo Vargas, Yucel Ustundag, Ramazan Idilman, Andreea M. Catana, Alvaro Urzúa, Ahmet Yavuz, Staffan Wahlin, Mesut Aydin, Cumali Efe, Laura Cristoferi, Hatef Massoumi, Maria Vincent, Sandro Ruiz Garcia, Evrim Kahramanoğlu-Aksoy, Natalia Ratusnu, Craig Lammert, Sümeyra Yıldırım, Mário Reis Álvares-da-Silva, Murat Harputoğlu, Marina Silveira, Murat Kiyici, Fátima Higuera-de la Tijera, Nurhan Demir, Cynthia Levy, Einar Bjornsson, Javier Brahm, Rotonya M. Carr, Nidah S. Khakoo, Andres Jose Gomez Aldana, Murat Akyildiz, Leyla Nazal, Alessio Gerussi, Tuğçe Eşkazan, Zeynep Ellik, Pietro Invernizzi, Fulya Gunsar, Ezequiel Ridruejo, Eleonora De Martin, Tugrul Purnak, Fatih Eren, Hüseyin Kaçmaz, Margarita Anders, Nikolaos K. Gatselis, Romee Snijders, Sezgin Barutçu, Costica Aloman, Alexandra Heurgue-Berlot, Bianca Magro, Jonathan Aguirre, Kader Irak, Koray Tascilar, Aldo J. Montano-Loza, Marcelo Silva, David N. Assis, Joost P.H. Drenth, Eira Cerda Reyes, Ibrahim Hatemi, Mirta Peralta, Sanjaya K. Satapathy, James L. Boyer, Yasemin H. Balaban, Efe, C, Lammert, C, Tascilar, K, Dhanasekaran, R, Ebik, B, Higuera-de la Tijera, F, Caliskan, A, Peralta, M, Gerussi, A, Massoumi, H, Catana, A, Purnak, T, Rigamonti, C, Aldana, A, Khakoo, N, Nazal, L, Frager, S, Demir, N, Irak, K, Melekoglu-Ellik, Z, Kacmaz, H, Balaban, Y, Atay, K, Eren, F, Alvares-da-Silva, M, Cristoferi, L, Urzua, A, Eskazan, T, Magro, B, Snijders, R, Barutcu, S, Lytvyak, E, Zazueta, G, Demirezer-Bolat, A, Aydin, M, Heurgue-Berlot, A, De Martin, E, Ekin, N, Yildirim, S, Yavuz, A, Biyik, M, Narro, G, Kiyici, M, Akyildiz, M, Kahramanoglu-Aksoy, E, Vincent, M, Carr, R, Gunsar, F, Reyes, E, Harputluoglu, M, Aloman, C, Gatselis, N, Ustundag, Y, Brahm, J, Vargas, N, Guzelbulut, F, Garcia, S, Aguirre, J, Anders, M, Ratusnu, N, Hatemi, I, Mendizabal, M, Floreani, A, Fagiuoli, S, Silva, M, Idilman, R, Satapathy, S, Silveira, M, Drenth, J, Dalekos, G, Assis, D, Bjornsson, E, Boyer, J, Yoshida, E, Invernizzi, P, Levy, C, Montano-Loza, A, Schiano, T, Ridruejo, E, Wahlin, S, Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı, Lammert, Craig, Taşçılar, Koray, Dhanasekaran, Renumathy, Ebik, Berat, Higuera-de la Tijera, Fatima, Çalışkan, Ali R., Peralta, Mirta, Gerussi, Alessio, Massoumi, Hatef, Catana, Andreea M., Purnak, Tuğrul, Rigamonti, Cristina, Aldana, Andres J. G., Khakoo, Nidah, Nazal, Leyla, Frager, Shalom, Demir, Nurhan, Irak, Kader, Melekoğlu-Ellik, Zeynep, Kaçmaz, Hüseyin, Balaban, Yasemin, Atay, Kadri, Eren, Fatih, Alvares-da-Silva, Mario R., Cristoferi, Laura, Urzua, Alvaro, Eskazan, Tugce, Magro, Bianca, Snijders, Romee, Barutçu, Sezgin, Lytvyak, Ellina, Zazueta, Godolfino M., Demirezer-Bolat, Aylin, Aydın, Mesut, Heurgue-Berlot, Alexandra, De Martin, Eleonora, Ekin, Nazım, Yıldırım, Sumeyra, Yavuz, Ahmet, Bıyık, Murat, Narro, Graciela C., Kıyıcı, Murat, Kahramanoğlu-Aksoy, Evrim, Vincent, Maria, Carr, Rotonya M., Günsar, Fulya, Reyes, Eira C., Harputluoğlu, Murat, Aloman, Costica, Gatselis, Nikolaos K., Üstündağ, Yücel, Brahm, Javier, Vargas, Nataly C. E., Güzelbulut, Fatih, Garcia, Sandro R., Aguirre, Jonathan, Anders, Margarita, Ratusnu, Natalia, Hatemi, İbrahim, Mendizabal, Manuel, Floreani, Annarosa, Fagiuoli, Stefano, Silva, Marcelo, İdilman, Ramazan, Satapathy, Sanjaya K., Silveira, Marina, Drenth, Joost P. H., Dalekos, George N., Assis, David N., Bjornsson, Einar, Boyer, James L., Yoshida, Eric M., Invernizzi, Pietro, Levy, Cynthia, Montano-Loza, Aldo J., Schiano, Thomas D., Ridruejo, Ezequiel, Wahlin, Staffan, and School of Medicine

Subjects
Adult, Male, medicine.medical_specialty, budesonide, Cirrhosis, Adolescent, Gastroenterology and hepatology, medicine.medical_treatment, Azathioprine, Autoimmune hepatitis, mercaptopurine, Liver transplantation, Gastroenterology, Young Adult, Sars-Cov-2 Infection, Internal medicine, medicine, Humans, Autoimmunity, Budesonide, Mercaptopurine, SARS-CoV-2, Aged, Retrospective Studies, Mechanical ventilation, Aged, 80 and over, azathioprine, liver transplantation, Hepatology, business.industry, autoimmunity, COVID-19, Immunosuppression, Odds ratio, Middle Aged, medicine.disease, Tacrolimus, Liver-Transplant Recipients, Hospitalization, Hepatitis, Autoimmune, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Pharmaceutical Preparations, Female, business, medicine.drug
Abstract

Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH., Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic), A. Gerussi, L. Cristoferi, and P. Invernizzi acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic).

Published
2021

18. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis

Author

J. Enrique Dominguez-Munoz, Asbjørn M. Drewes, Björn Lindkvist, Nils Ewald, László Czakó, Jonas Rosendahl, J. Matthias Löhr, Matthias Löhr, Marc Besselink, Julia Mayerle, Markus M. Lerch, Fatih Akisik, Nikolaos Kartalis, Riccardo Manfredi, Julio Iglesias-Garcia, Stephan L. Haas, Jutta Keller, Marja A. Boermeester, Jens Werner, Jean-Marc Dumonceau, Paul Fockens, Asbjørn Drewes, Güralp O. Cheyan, Joost P. Drenth, Philip Hardt, Enrique de Madaria, Christian Gheorghe, Fredrik Lindgren, Alexander Schneider, Heiko Witt, Thomas Bollen, Piero Boraschi, Jens B. Frøkjær, Sasa Rudolf, Marco Bruno, Georg Dimcevski, Marc Giovannini, Aldis Pukitis, Mariachiara Petrone, Kofi Oppong, Basil Ammori, Helmut Friess, Jakob R. Izbiki, Paula Ganeh, Roberto Salvia, Alain Sauvanet, Sorin Barbu, Vladimir Lyadov, Pierre Deprez, Natalja Gubergrits, Alexey V. Okhlobystiy, Marianna Arvanitakis, Guido Costamagna, Akos Pap, Roland Andersson, Truls Hauge, Colin McKay, Aldos Pukitis, Sara Regnér, Peter Dite´, Søren S. Olesen, Sinead Duggan, Andrew Hopper, Mary Phillips, Oleg Shvets, Miroslav Vujasinovic, Laszlo Czako, Lorenzo Piemonti, Hemant Kocher, Vinciane Rebours, Davor Stimac, Peter Hegyi, Gastroenterology & Hepatology, Surgery, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, AII - Inflammatory diseases, APH - Methodology, Gastroenterology and Hepatology, Dominguez-Munoz, J. Enrique, Drewes, Asbjørn M., Lindkvist, Björn, Ewald, Nil, Czakó, László, Rosendahl, Jona, Löhr, J. Matthia, Löhr, Matthia, Besselink, Marc, Mayerle, Julia, Lerch, Markus M., Akisik, Fatih, Kartalis, Nikolao, Manfredi, Riccardo, Iglesias-Garcia, Julio, Haas, Stephan L., Keller, Jutta, Boermeester, Marja A., Werner, Jen, Dumonceau, Jean-Marc, Fockens, Paul, Drewes, Asbjørn, Cheyan, Güralp O., Drenth, Joost P., Hardt, Philip, de Madaria, Enrique, Gheorghe, Christian, Lindgren, Fredrik, Schneider, Alexander, Witt, Heiko, Bollen, Thoma, Boraschi, Piero, Frøkjær, Jens B., Rudolf, Sasa, Bruno, Marco, Dimcevski, Georg, Giovannini, Marc, Pukitis, Aldi, Petrone, Mariachiara, Oppong, Kofi, Ammori, Basil, Friess, Helmut, Izbiki, Jakob R., Ganeh, Paula, Salvia, Roberto, Sauvanet, Alain, Barbu, Sorin, Lyadov, Vladimir, Deprez, Pierre, Gubergrits, Natalja, Okhlobystiy, Alexey V., Arvanitakis, Marianna, Costamagna, Guido, Pap, Ako, Andersson, Roland, Hauge, Trul, Mckay, Colin, Pukitis, Aldo, Regnér, Sara, Dite´, Peter, Olesen, Søren S., Duggan, Sinead, Hopper, Andrew, Phillips, Mary, Shvets, Oleg, Vujasinovic, Miroslav, Czako, Laszlo, Piemonti, Lorenzo, Kocher, Hemant, Rebours, Vinciane, Stimac, Davor, and Hegyi, Peter

Subjects
Development and evaluation (GRADE) Guidelines Pancreatic exocrine insufficiency, Chronic pancreatiti, Endocrinology, Diabetes and Metabolism, Disease, Guideline, Development and evaluation (GRADE), Gastroenterology, 0302 clinical medicine, Pseudocyst, Diabetes mellitus, Medicine, 03.02. Klinikai orvostan, Pancreas enzyme, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Evidence-Based Medicine, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Chronic pancreatitis, Quality of life, Diabetes mellitu, medicine.medical_specialty, Evidence-based practice, Pancreatic pseudocyst, Pain, Guidelines, chronic pancreatitis, 03 medical and health sciences, Pain Pseudocyst, Internal medicine, Pancreatitis, Chronic, Pancreatic Pseudocyst, medical and surgical management of chronic pancreatitis based on current available evidence, Pancreatic exocrine insufficiency, Humans, Pain Management, Exocrine pancreatic insufficiency, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, Hepatology, business.industry, Endoscopic therapy, Endoscopy, medicine.disease, Malnutrition, Clinical research, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Grading of recommendations assessment, Pancreatitis, Exocrine Pancreatic Insufficiency, business
Abstract

Item does not contain fulltext BACKGROUND: In collaboration with United European Gastroenterology, the working group on 'Harmonizing diagnosis and treatment of chronic pancreatitis across Europe' (HaPanEU) developed European guidelines for the management of chronic pancreatitis using an evidence-based approach. METHODS: Recommendations of multidisciplinary review groups based on systematic literature reviews to answer predefined clinical questions are summarised. Recommendations are graded using the Grading of Recommendations Assessment, Development and Evaluation system. RESULTS: Recommendations covered topics related to the clinical management of chronic pancreatitis: aetiology, diagnosis of chronic pancreatitis with imaging, diagnosis of pancreatic exocrine insufficiency, surgical therapy, medical therapy, endoscopic therapy, treatment of pancreatic pseudocysts, pancreatic pain, nutrition and malnutrition, diabetes mellitus and the natural course of the disease and quality of life. CONCLUSIONS: The HaPanEU/United European Gastroenterology guidelines provide evidence-based recommendations concerning key aspects of the medical and surgical management of chronic pancreatitis based on current available evidence. These recommendations should serve as a reference standard for existing management of the disease and as a guide for future clinical research. This article summarises the HaPanEU recommendations and statements.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results